S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Forecast, Price & News

$16.06
-0.07 (-0.43%)
(As of 06/2/2023 ET)
Compare
Today's Range
$16.06
$16.44
50-Day Range
$14.05
$16.79
52-Week Range
$12.82
$16.91
Volume
40,379 shs
Average Volume
78,052 shs
Market Capitalization
$29.06 billion
P/E Ratio
42.26
Dividend Yield
0.93%
Price Target
N/A

Astellas Pharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
28.41%
From $0.88 to $1.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars


ALPMY stock logo

About Astellas Pharma (OTCMKTS:ALPMY) Stock

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update
Astellas Pharma (OTCMKTS:ALPMY) Raised to "Buy" at Citigroup
See More Headlines

ALPMY Price History

ALPMY Company Calendar

Last Earnings
4/27/2023
Today
6/03/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,522
Year Founded
1923

Profitability

Net Income
$730.68 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.24 billion
Cash Flow
$0.95 per share
Book Value
$6.52 per share

Miscellaneous

Outstanding Shares
1,809,663,000
Free Float
N/A
Market Cap
$29.06 billion
Optionable
Not Optionable
Beta
0.59

Social Links


Key Executives

  • Naoki Okamura
    President, CEO & Representative Director
  • Minoru Kikuoka
    Chief Financial Officer & Head-Finance
  • Tadaaki Taniguchi
    Chief Medical Officer
  • Yoshitsugu Shitaka
    Chief Scientific Officer & Head-Research
  • Katsuyoshi Sugita
    Head-Personnel & Compliance













ALPMY Stock - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALPMY shares.
View ALPMY analyst ratings
or view top-rated stocks.

How have ALPMY shares performed in 2023?

Astellas Pharma's stock was trading at $15.16 at the beginning of the year. Since then, ALPMY shares have increased by 5.9% and is now trading at $16.06.
View the best growth stocks for 2023 here
.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 37,400 shares, an increase of 77.3% from the April 30th total of 21,100 shares. Based on an average trading volume of 89,000 shares, the short-interest ratio is currently 0.4 days.
View Astellas Pharma's Short Interest
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings data on Thursday, April, 27th. The company reported $0.15 EPS for the quarter. The business had revenue of $2.68 billion for the quarter. Astellas Pharma had a trailing twelve-month return on equity of 12.64% and a net margin of 6.27%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.15 per share and currently has a dividend yield of 1.98%. The dividend payout ratio is 39.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ALPMY will have a dividend payout ratio of 13.27% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Astellas Pharma's stock split?

Shares of Astellas Pharma split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $16.06.

How much money does Astellas Pharma make?

Astellas Pharma (OTCMKTS:ALPMY) has a market capitalization of $29.06 billion and generates $11.24 billion in revenue each year. The company earns $730.68 million in net income (profit) each year or $0.38 on an earnings per share basis.

How many employees does Astellas Pharma have?

The company employs 14,522 workers across the globe.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The official website for the company is www.astellas.com. The company can be reached via phone at (133) 244-3000.

This page (OTCMKTS:ALPMY) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -